NCT05072015Not yet recruiting
Systematic Follow up of Second Line Treatments for Parkinson's Disease (Deep Brain Stimulation, Apomorphin Pump, Duodopa Pump)
Source: ClinicalTrials.gov · Last updated 17 Feb 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Primary purpose: Fluctuations and dyskinesia evolution in Parkinson's disease patients, one year after initiation of deep brain stimulation, apomorphin pump or duodopa pump Secundary purposes: * Motor complications evolution at 6 months, 2 and 3 years * MDS UPDRS III score at 6 months, 1, 2 and 3 years * non motor complications evolution at 6 months, 1, 2 and 3 years * cognition and psychiatric complications evolution at 6 months, 1, 2 and 3 years * cutaneous and digestive complications at 6 months, 1, 2 and 3 years * neuropathy occurrence at 6 months, 1, 2 and 3 years * medical treatment and Levodopa equivalent dose modifications at 6 months, 1, 2 and 3 years
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 30 Sept 2021
- Start date
- 1 Feb 2022
- Primary completion date
- 28 Feb 2022
- Lead sponsor
- University Hospital, Strasbourg, France
- Diseases
- Parkinson disease
- NCT number
- NCT05072015
What you commit to
- Study type: Observational
- Planned participants: 150
- From 1 Feb 2022 to the primary completion date, 28 Feb 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- patient with another parkinsonian syndrome than Parkinson' s disease
Other
- patient who did not give his acceptation for the protocol
- MOCA\<20
- Patient who does not need second line treatment
Who the study is looking for
- Parkinson disease (UKPDSSB criteria)
- Patient with fluctuations and/or dyskinesia , who need treatment with deep brain stimulation, apomorphin pump or duodopa pump
- MOCA \>20
- patient \>21 years of age
- patient who has signed protocol acceptation
Age in the registry: 21 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mathieu ANHEIM Coordinator of this site? Confirm its status | Strasbourg | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.